Apr 18, 2024 4:30pm EDT Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Apr 3, 2024 8:05am EDT Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension